These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35231576)

  • 1. Pyrizolo[1,5-a]pyrimidine derivatives of the second-generation TRK inhibitor: Design, synthesis and biological evaluation.
    Fan Y; Zhang Y; Liu Y; Jiang H; Zhou Y; Tang C; Fan W
    Bioorg Med Chem Lett; 2022 May; 63():128646. PubMed ID: 35231576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 3-pyrazolyl-substituted pyrazolo[1,5-a]pyrimidine derivatives as potent TRK inhibitors to overcome clinically acquired resistance.
    Gong Y; Wu FX; Wang MS; Xu HC; Zhuo LS; Yang GF; Huang W
    Eur J Med Chem; 2022 Nov; 241():114654. PubMed ID: 35961071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrazolo[1,5-
    Mahajan AT; Shivani ; Datusalia AK; Coluccini C; Coghi P; Chaudhary S
    Molecules; 2024 Jul; 29(15):. PubMed ID: 39124968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
    Drilon A; Ou SI; Cho BC; Kim DW; Lee J; Lin JJ; Zhu VW; Ahn MJ; Camidge DR; Nguyen J; Zhai D; Deng W; Huang Z; Rogers E; Liu J; Whitten J; Lim JK; Stopatschinskaja S; Hyman DM; Doebele RC; Cui JJ; Shaw AT
    Cancer Discov; 2018 Oct; 8(10):1227-1236. PubMed ID: 30093503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of macrocyclic derivatives as TRK inhibitors.
    Li P; Cai S; Zhao T; Xu L; Guan D; Li J; Zhou J; Zhang H
    Bioorg Med Chem Lett; 2021 Dec; 53():128409. PubMed ID: 34628036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel indazole derivatives as second-generation TRK inhibitors.
    Qin Q; Lu S; Guo Z; Li Z; Fu Q; Wang X; Wu T; Sun Y; Liu N; Zhang H; Zhao D; Cheng M
    Eur J Med Chem; 2024 Oct; 276():116640. PubMed ID: 39033612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells.
    Suzuki C; Nishiyama A; Arai S; Tange S; Tajima A; Tanimoto A; Fukuda K; Takumi Y; Kotani H; Takeuchi S; Yanagimura N; Ohtsubo K; Yamamoto N; Omori K; Yano S
    Cancer Sci; 2022 Jul; 113(7):2323-2335. PubMed ID: 35363931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and Structure-Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors.
    Duan Y; Wang J; Zhu S; Tu ZC; Zhang Z; Chan S; Ding K
    Eur J Med Chem; 2020 Oct; 203():112552. PubMed ID: 32702585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation.
    Zhuo LS; Wang MS; Wu FX; Xu HC; Gong Y; Yu ZC; Tian YG; Pang C; Hao GF; Huang W; Yang GF
    J Med Chem; 2021 Oct; 64(20):15503-15514. PubMed ID: 34668694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations.
    Wang Z; Wang J; Wang Y; Xiang S; Zhou H; Song S; Song X; Tu Z; Zhou Y; Ding K; Zhang ZM; Zhang Z; Lu X
    J Med Chem; 2023 Sep; 66(18):12950-12965. PubMed ID: 37676745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel 3-(1H-pyrazol-4-yl)-1H-indazole derivatives as potent type II TRK inhibitors against acquired resistance.
    Qin Q; Guo Z; Lu S; Wang X; Fu Q; Wu T; Sun Y; Liu N; Zhang H; Zhao D; Cheng M
    Eur J Med Chem; 2024 Jan; 264():115953. PubMed ID: 38029466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological activity of bicyclic carboxamide derivatives as TRK inhibitors.
    Sun M; Cai S; Li P; Zhang F; Zhang H; Zhou J
    Bioorg Med Chem; 2020 Dec; 28(23):115811. PubMed ID: 33069129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer.
    Liu Z; Yu P; Dong L; Wang W; Duan S; Wang B; Gong X; Ye L; Wang H; Tian J
    J Med Chem; 2021 Jul; 64(14):10286-10296. PubMed ID: 34253025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and evaluate of indazolylaminoquinazoline derivatives as potent Tropomyosin receptor kinase (TRK) inhibitors.
    Xu Y; Zhao W; Zhang X; Yu X; Chen Y; Wang Z; Chu Y; Zhu X; Zhang P
    Bioorg Med Chem; 2024 Feb; 99():117608. PubMed ID: 38271867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of WO2015042088 A1 - a novel urea-based scaffold for TrkA inhibition.
    Bernard-Gauthier V; Schirrmacher R
    Expert Opin Ther Pat; 2016; 26(2):291-5. PubMed ID: 26561352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of novel indolin-2-one derivatives as potent second-generation TRKs inhibitors.
    Qin Q; Fu Q; Wang X; Lv R; Lu S; Guo Z; Wu T; Sun Y; Sun Y; Liu N; Zhao D; Cheng M
    Eur J Med Chem; 2023 May; 253():115291. PubMed ID: 37030091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
    Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
    Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and structural analysis of a selective tropomyosin receptor kinase C (TRKC) inhibitor.
    Wang Z; Ren J; Jia K; Zhao Y; Liang L; Cheng Z; Huang F; Zhao X; Cheng J; Song S; Sheng T; Wan W; Shu Q; Wu D; Zhang J; Lu T; Chen Y; Ran T; Lu S
    Eur J Med Chem; 2022 Nov; 241():114601. PubMed ID: 35872544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrazolo[1,5-a]pyrimidine based Trk inhibitors: Design, synthesis, biological activity evaluation.
    Zhang Y; Liu Y; Zhou Y; Zhang Q; Han T; Tang C; Fan W
    Bioorg Med Chem Lett; 2021 Jan; 31():127712. PubMed ID: 33246108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A
    Ann Oncol; 2019 Nov; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.